Nohla Therapeutics is a cell therapy company focused on the development of universal, off-the shelf therapies for cancer patients. Nohla’s technology platform enables the generation and rapid expansion of key cancer-fighting cells from umbilical cord blood, without any requirement for HLA matching. The company is currently evaluating a number of potential programs from its proprietary cell therapy platform focusing on the Notch signaling pathway. The pipeline includes an off-the-shelf CAR-NK cell therapy and a next-generation 3-D platform that has the potential to significantly expand adult HSPCs while maintaining their functionality.
In May 2018, Nohla announced the closing of a $56 million Series B financing. In this round, Fidelity Management and Research Company and Celgene Corporation (Nasdaq: CELG) joined existing investors, ARCH Venture Partners, 5AM Ventures, Alexandria Venture Investments and AML Biotech Partners, who also participated in the financing. To date, the company has raised approximately $110 million.